Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)

Recruiting

HPV DosesComparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)

Sponsor:

The University of Texas Medical Branch, Galveston

Code:

NCT05672927

Conditions

Immunization

HPV Infection

Human Papillomavirus

Eligibility Criteria

Sex: Female

Age: 27 - 45

Healthy Volunteers: Accepted

Interventions

9-valent HPV vaccine, 2 doses alternate timing

9-valent HPV vaccine, 3 doses standard timing

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-01-10. This information was provided to ClinicalTrials.gov by The University of Texas Medical Branch, Galveston on 2025-10-06.